Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftolozane/tazobactam continuous-infusion OPAT for bronchiectasis and cystic fibrosis exacerbations
ACTRN12623000976684Phase 4Not yet recruiting
- Sponsor
- Sunshine Coast Hospital and Health Service
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ceftolozane + tazobactam in bronchiectasis and cystic fibrosis (CF), sponsored by Sunshine Coast Hospital and Health Service. Primary endpoint: Feasibility of ceftolozane/tazobactam continuous infusion in OPAT. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
ceftolozane + tazobactam
03
Conditions
bronchiectasiscystic fibrosis (CF)
Beyond the preview
Go deeper on ACTRN12623000976684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000976684.